Presentation 1: Micropeptide Control of Cardiac Rhythm, presented by Douglas M. Anderson, PhD, Assistant Professor of Medicine, Department of Medicine, Aab Cardiovascular Research Institute, Presentation 2: Managing diabetes in patients on antipsychotics: Is early aggressive therapy superior to standard of care, presented by Susanne Miedlich, MD, Assistant Professor of Medicine, Department of Medicine, Division of Endocrinology, Both: University of Rochester Medical Center.
At the conclusion of this presentation participants should be able to:
1. Micropeptides are small proteins (~50 amino acids in length) which are encoded by small open reading frames, many of which remain concealed in putatively annotated long noncoding RNAs.
2. The novel cardiac micropeptide, named KCNEmini, directly regulates the function of voltage-gated potassium channels in the heart, which is important for maintaining normal cardiac rhythm and contractility.
3. KCNEmini may be a novel candidate gene for human arrhythmias, such as Long QT Syndrome.
1. Understand the impact of antipsychotic medications on metabolic health.
2. Learn about potential risk factors for diabetes in the above patients.
3. Learn about promising therapeutic approaches to treat diabetes early in the above patients.
The University of Rochester School of Medicine and Dentistry designates this live educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Tuesday, July 16, 2019 at 12:00pm to 1:00pm
Class of '62 Auditorium
601 Elmwood Avenue, Rochester, NY 14642